Biotech · Private company
Kartos Therapeutics, Inc.
Track this companyFree. Adds Kartos Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials164 recruiting or active
Pipeline programs24From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline24
- Best Available Therapy (BAT)Phase 3 · Primary Myelofibrosis (PMF)ClinicalTrials.gov · fetched Nov 12, 2026
- KRT-232Phase 3 · Primary Myelofibrosis (PMF)ClinicalTrials.gov · fetched Nov 12, 2026
- NavtemadlinPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- NavtemadlinPhase 3 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- RuxolitinibPhase 3 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- acalabrutinibPhase 2 · Diffuse Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AvelumabPhase 2 · Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CytarabinePhase 2 · Relapsed or Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- DasatinibPhase 2 · Chronic Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- DecitabinePhase 2 · Relapsed or Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- KRT-232Phase 2 · Polycythemia VeraClinicalTrials.gov · fetched Nov 12, 2026
- KRT-232Phase 2 · Chronic Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- KRT-232Phase 2 · Diffuse Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- KRT-232Phase 2 · Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- KRT-232Phase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- KRT-232Phase 2 · Relapsed or Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- KRT-232Phase 2 · Small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- NilotinibPhase 2 · Chronic Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- RuxolitinibPhase 2 · Polycythemia VeraClinicalTrials.gov · fetched Nov 12, 2026
- TL-895Phase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- TL-895Phase 2 · Primary Myelofibrosis (PMF)ClinicalTrials.gov · fetched Nov 12, 2026
- AMG 232Phase 1 · Advanced MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- DabrafenibPhase 1 · Advanced MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- TrametinibPhase 1 · Advanced MalignancyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibPHASE3 · RECRUITING · started Jun 3, 2024ClinicalTrials.gov NCT06479135 · fetched Nov 12, 2026
- Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerPHASE2_PHASE3 · RECRUITING · started Jul 17, 2023ClinicalTrials.gov NCT05797831 · fetched Nov 12, 2026
- KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung CancerPHASE2 · TERMINATED · started Dec 6, 2021ClinicalTrials.gov NCT05027867 · fetched Nov 12, 2026
- KRT-232 and TKI Study in Chronic Myeloid LeukemiaPHASE1_PHASE2 · UNKNOWN · started May 7, 2021ClinicalTrials.gov NCT04835584 · fetched Nov 12, 2026
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisPHASE2 · UNKNOWN · started Apr 13, 2021ClinicalTrials.gov NCT04878003 · fetched Nov 12, 2026
- TL-895 and KRT-232 Study in Acute Myeloid LeukemiaPHASE1_PHASE2 · UNKNOWN · started Mar 31, 2021ClinicalTrials.gov NCT04669067 · fetched Nov 12, 2026
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLPHASE1_PHASE2 · RECRUITING · started Feb 23, 2021ClinicalTrials.gov NCT04502394 · fetched Nov 12, 2026
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibPHASE1_PHASE2 · UNKNOWN · started Jan 28, 2021ClinicalTrials.gov NCT04485260 · fetched Nov 12, 2026
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFPHASE1_PHASE2 · UNKNOWN · started Nov 17, 2020ClinicalTrials.gov NCT04640532 · fetched Nov 12, 2026
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)PHASE1_PHASE2 · TERMINATED · started Sep 25, 2019ClinicalTrials.gov NCT04113616 · fetched Nov 12, 2026
- Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaPHASE1_PHASE2 · UNKNOWN · started Mar 19, 2019ClinicalTrials.gov NCT03787602 · fetched Nov 12, 2026
- KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentPHASE2_PHASE3 · UNKNOWN · started Jan 15, 2019ClinicalTrials.gov NCT03662126 · fetched Nov 12, 2026
- KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia VeraPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 15, 2019ClinicalTrials.gov NCT03669965 · fetched Nov 12, 2026
- A Phase 1b/2a Study Evaluating AMG 232 in Metastatic MelanomaPHASE1 · COMPLETED · started Dec 19, 2014ClinicalTrials.gov NCT02110355 · fetched Nov 12, 2026
- A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid LeukemiaPHASE1 · COMPLETED · started Apr 1, 2014ClinicalTrials.gov NCT02016729 · fetched Nov 12, 2026
- A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple MyelomaPHASE1 · COMPLETED · started Dec 27, 2012ClinicalTrials.gov NCT01723020 · fetched Nov 12, 2026